Brain Tumor Program (Neuro-Oncology)
Phone: (410) 955-8837
The Brain Tumor Program at the Kimmel Cancer Center is a member of the Adult Brain Tumor Consortium (ABTC), a group of 16 medical centers dedicated to improving treatments for adults with malignant brain tumors by initiating early phase clinical trials and collaborations with researchers and other clinical trials groups. The central office for ABTC is located at Johns Hopkins, and Dr. Stuart Grossman is the group's co-director.
Faculty and staff in the Brain Tumor Program also are members of the Johns Hopkins Radiosurgery Group and treat many different brain conditions, both benign and malignant.
Faculty in the Brain Tumor Program focus on clinical research and treatment of primary brain tumors, neoplastic meningitis, brain metastases, epidural cord compression, neurotoxicities, anticancer agents, and cancer pain management.
More information about brain tumor treatments also can be found through the Johns Hopkins Department of Neurology and Neurosurgery. Radiation therapy services, offered through the Department of Radiation Oncology, encompass a wide variety of brain and spine tumor therapies and expert consultation.
Patients with metastatic tumors to the brain (tumors that begin elsewhere but spread to the brain) can learn about treatments and research at the Metastatic Brain Tumor Center.
New Research Project: Cytomegalovirus (CMV)
Johns Hopkins scientists are conducting research in high-grade glioma patients to measure the blood levels of cytomegalovirus (CMV), a common virus that can cause severe disease in patients with weakened immune systems. Glioma patients can experience weakened immune systems as a result of therapies like radiation, chemotherapy and high-dose steroids used to treat their cancer. The scientists will analyze whether blood levels of CMV in high-grade glioma patients currently receiving standard therapies correlate with changes in blood counts, an indicator of a therapy’s success or failure. Ultimately, the Johns Hopkins investigators hope to determine whether high-grade glioma patients should be routinely screened for CMV and if antiviral medications or treatment may have an impact on outcomes. Learn more and support this research.